Ancillary approaches to plasminogen activators

Reza Bavarsad Shahripour, Andrei Alexandrov

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Acute ischemic stroke develops from an interruption in focal cerebral blood flow. In many cases, it is caused by an acute thromboembolism. Although systemic fibrinolytic therapy for acute ischemic stroke has been a significant breakthrough in the management of this disease, additional agents and methods that could improve or restore cerebral flow are necessary. Similarly to findings in acute myocardial infarction, combination pharmacotherapy has the potential to improve current thrombolytic treatment in acute ischemic stroke. In recent years, research efforts were directed toward various combination therapy with pharmacological and nonpharmacological methods. Several trials tested tissue plasminogen activator (t-PA) in combination with antiplateletes and anticoagulants. Combination of t-PA with nonpharmacological agents included sonothrombolysis (amplifying the thrombolytic effect), laser (neuro-recovery), hypothermia (cytoprotection and decreasing brain swelling), and blood flow augmentation (increasing residual flow and recruitment of collateral vessels). This paper will review ongoing clinical trials and safety of these promising combinatory treatments.

Original languageEnglish (US)
Pages (from-to)113-119
Number of pages7
JournalAnnals of the New York Academy of Sciences
Volume1268
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Plasminogen Activators
Tissue Plasminogen Activator
Blood
Stroke
Hypothermia
Drug therapy
Cerebrovascular Circulation
Anticoagulants
Swelling
Brain
Cytoprotection
Thrombolytic Therapy
Thromboembolism
Brain Edema
Disease Management
Recovery
Lasers
Therapeutics
Myocardial Infarction
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Ancillary approaches to plasminogen activators. / Bavarsad Shahripour, Reza; Alexandrov, Andrei.

In: Annals of the New York Academy of Sciences, Vol. 1268, No. 1, 01.01.2012, p. 113-119.

Research output: Contribution to journalArticle

Bavarsad Shahripour, Reza ; Alexandrov, Andrei. / Ancillary approaches to plasminogen activators. In: Annals of the New York Academy of Sciences. 2012 ; Vol. 1268, No. 1. pp. 113-119.
@article{388e34217a814e81a877363986652124,
title = "Ancillary approaches to plasminogen activators",
abstract = "Acute ischemic stroke develops from an interruption in focal cerebral blood flow. In many cases, it is caused by an acute thromboembolism. Although systemic fibrinolytic therapy for acute ischemic stroke has been a significant breakthrough in the management of this disease, additional agents and methods that could improve or restore cerebral flow are necessary. Similarly to findings in acute myocardial infarction, combination pharmacotherapy has the potential to improve current thrombolytic treatment in acute ischemic stroke. In recent years, research efforts were directed toward various combination therapy with pharmacological and nonpharmacological methods. Several trials tested tissue plasminogen activator (t-PA) in combination with antiplateletes and anticoagulants. Combination of t-PA with nonpharmacological agents included sonothrombolysis (amplifying the thrombolytic effect), laser (neuro-recovery), hypothermia (cytoprotection and decreasing brain swelling), and blood flow augmentation (increasing residual flow and recruitment of collateral vessels). This paper will review ongoing clinical trials and safety of these promising combinatory treatments.",
author = "{Bavarsad Shahripour}, Reza and Andrei Alexandrov",
year = "2012",
month = "1",
day = "1",
doi = "10.1111/j.1749-6632.2012.06688.x",
language = "English (US)",
volume = "1268",
pages = "113--119",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Ancillary approaches to plasminogen activators

AU - Bavarsad Shahripour, Reza

AU - Alexandrov, Andrei

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Acute ischemic stroke develops from an interruption in focal cerebral blood flow. In many cases, it is caused by an acute thromboembolism. Although systemic fibrinolytic therapy for acute ischemic stroke has been a significant breakthrough in the management of this disease, additional agents and methods that could improve or restore cerebral flow are necessary. Similarly to findings in acute myocardial infarction, combination pharmacotherapy has the potential to improve current thrombolytic treatment in acute ischemic stroke. In recent years, research efforts were directed toward various combination therapy with pharmacological and nonpharmacological methods. Several trials tested tissue plasminogen activator (t-PA) in combination with antiplateletes and anticoagulants. Combination of t-PA with nonpharmacological agents included sonothrombolysis (amplifying the thrombolytic effect), laser (neuro-recovery), hypothermia (cytoprotection and decreasing brain swelling), and blood flow augmentation (increasing residual flow and recruitment of collateral vessels). This paper will review ongoing clinical trials and safety of these promising combinatory treatments.

AB - Acute ischemic stroke develops from an interruption in focal cerebral blood flow. In many cases, it is caused by an acute thromboembolism. Although systemic fibrinolytic therapy for acute ischemic stroke has been a significant breakthrough in the management of this disease, additional agents and methods that could improve or restore cerebral flow are necessary. Similarly to findings in acute myocardial infarction, combination pharmacotherapy has the potential to improve current thrombolytic treatment in acute ischemic stroke. In recent years, research efforts were directed toward various combination therapy with pharmacological and nonpharmacological methods. Several trials tested tissue plasminogen activator (t-PA) in combination with antiplateletes and anticoagulants. Combination of t-PA with nonpharmacological agents included sonothrombolysis (amplifying the thrombolytic effect), laser (neuro-recovery), hypothermia (cytoprotection and decreasing brain swelling), and blood flow augmentation (increasing residual flow and recruitment of collateral vessels). This paper will review ongoing clinical trials and safety of these promising combinatory treatments.

UR - http://www.scopus.com/inward/record.url?scp=84866566118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866566118&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2012.06688.x

DO - 10.1111/j.1749-6632.2012.06688.x

M3 - Article

C2 - 22994229

AN - SCOPUS:84866566118

VL - 1268

SP - 113

EP - 119

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -